Study Title
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
Study Details
Description:
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals (Clarity Clinical)clinicaltrials@claritypharmaceuticals.com
+61 0 2 9209 4037
Government Study Link:
NCT04023331 - Click here to see study onClinicalTrials.gov
Inclusion
- • Known high-risk neuroblastoma OR previously intermediate-risk neuroblastoma that has relapsed
- • Karnofsky or Lansky performance status ≥50;
- • Adequate liver function
- • Adequate renal function
Exclusion
- • Any other active malignancy, or a history of prior malignancy within the past 3 years;
- • Participants with disease of any major organ system that would compromise their ability to tolerate therapy
- • History of cardiac failure
- • Participants who are on hemodialysis
- • Any medical condition which the Investigator feels may interfere with the procedures or evaluations of the study
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations